Business
Kyowa Kirin Announces Late-Breaking Abstract Presentation at the European Academy of Dermatology and Venerology Congress
Princeton, NJ and TOKYO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET-SHUTTLE trial of rocatinlimab, an investigational T-cell rebalancing therapy, will be presented as a late breaking oral presentation at the European Academy of Dermatology and Venerology (EADV) 2025 Annual Meeting to be held in Paris, France from September 17-20, 2025. This trial assessed the efficacy and safety of rocatinlimab every 4 weeks in combinat
About this update from Kyowa Kirin Co., Ltd.
[{"type":"text","content":"Princeton, NJ and TOKYO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET-SHUTTLE trial of rocatinlimab, an investigational T-cell rebalancing therapy, will be presented as a late breaking oral presentation at the European Academy of Dermatology and Venerology (EADV) 2025 Annual Meeting to be held in Paris, France from September 17-20, 2025. This trial assessed the efficacy and safety of rocatinlimab every 4 weeks in combination with topical corticosteroids and/or topical calcineurin inhibitors in adults with moderate-to-severe atopic dermatitis (AD).","length":628,"tagName":"p"},{"type":"text","content":"Moderate-to-severe AD is a chronic inflammatory skin disease that can cause severe itching and pain. Despite available treatment options, there remains a significant unmet need as some patients with moderate to severe AD fail to achieve or sustain treatment goals.","length":264,"tagName":"p"},{"type":"text","content":"Title: Rocatinlimab with Concomitant Topical Therapy Significantly Improved Clinical Signs and Symptoms of Atopic Dermatitis in Adults: Results from the Phase 3 ROCKET-SHUTTLE Trial","length":181,"tagName":"p"},{"type":"text","content":"Presenter: Eric Simpson, MD, MCRDate: Thursday, Sept. 18thTime: 15:00-15:15 CESTLocation: Paris Convention Centre, Paris NORD","length":128,"tagName":"p"},{"type":"text","content":"About the ROCKET Phase 3 ProgramROCKET is a comprehensive, global Phase 3 clinical trial program comprised of eight studies intended to establish the safety and efficacy profile of rocatinlimab in adults and adolescents with moderate to severe atopic dermatitis (AD) as well as multiple dosing regimens.","length":304,"tagName":"p"},{"type":"text","content":"About Moderate to Severe Atopic DermatitisAtopic dermatitis, the most common form of eczema, is a chronic inflammatory disease that causes excessively dry, itchy skin that can be painful. People with moderate to severe atopic dermatitis experience chronic symptoms, intensified by unpredictable flare-ups that can be painful and disruptive to everyday life. More than half of these patients report severe itching, leading to repeated scratching which can cause the skin to thicken and become vulnerable to infection. Atopic dermatitis (all severities) affects 15-20% of children and up to ...